Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 15 results.
User Information
Export Records
  1. 1.   Multidrug Efflux Pumps and Cancer Stem Cells: Insights Into Multidrug Resistance and Therapeutic Development
  2. Moitra, K.; Lou, H.; Dean, M.
  3. Clinical Pharmacology & Therapeutics. 2011, Apr; 89(4): 491-502.
  1. 2.   Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
  2. Sissung, T. M.; Gardner, E. R.; Piekarz, R. L.; Howden, R.; Chen, X. H.; Woo, S.; Franke, R.; Clark, J. A.; Miller-DeGraff, L.; Steinberg, S. M.; Venzon, D.; Liewehr, D.; Kleeberger, S. R.; Bates, S. E.; Price, D. K.; Rosing, D. R.; Cabell, C.; Sparreboom, A.; Figg, W. D.
  3. Clinical Cancer Research. 2011, Feb; 17(4): 937-946.
  1. 3.   Pharmacogenetics of Membrane Transporters: An Update on Current Approaches
  2. Sissung, T. M.; Baum, C. E.; Kirkl, C. T.; Gao, R.; Gardner, E. R.; Figg, W. D.
  3. Molecular Biotechnology. 2010, Feb; 44(2): 152-167.
  1. 4.   Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability
  2. Potocnik, U.; Glavac, D.; Dean, M.
  3. Cancer Genetics and Cytogenetics. 2008 183(1): 28-34.
  1. 5.   Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
  2. Gardner, E. R.; Burger, H.; van Schaik, R. H.; van Oosterom, A. T.; de Bruijn, E. A.; Guetens, G.; Prenen, H.; de Jong, F. A.; Baker, S. D.; Bates, S. E.; Figg, W. D.; Verweij, J.; Sparreboom, A.; Nooter, K.
  3. Clinical Pharmacology & Therapeutics. 2006, Aug; 80(2): 192-201.
  1. 6.   Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort
  2. Robertson, S. M.; Formentini, E.; Alfaro, R. M.; Natarajan, V.; Falloon, J.; Penzak, S. R.
  3. British Journal of Clinical Pharmacology. 2006, Apr; 61(4): 379-388.
  1. 7.   Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
  2. Lepper, E. R.; Baker, S. D.; Permenter, M.; Ries, N.; van Schaik, R. H. N.; Schenk, P. W.; Price, D. K.; Ahn, D.; Smith, N. F.; Cusatis, G.; Ingersoll, R. G.; Bates, S. E.; Mathijssen, R. H. J.; Verweij, J.; Figg, W. D.; Sparreboom, A.
  3. Clinical Cancer Research. 2005, OCT 15; 11(20): 7398-7404.
  1. 8.   Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis
  2. Potocnik, U.; Ferkolj, I.; Glavac, D.; Dean, M.
  3. Genes and Immunity. 2004, NOV; 5(7): 530-539.
  1. 9.   Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
  2. Penzak, S. R.; Shen, J. M.; Alfaro, R. M.; Remaley, A. T.; Natarajan, V.; Falloon, J.
  3. Therapeutic Drug Monitoring. 2004 26(3): 322-330.
  1. 10.   Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay
  2. Mi, Q. W.; Cui, B. L.; Silva, G. L.; Lantvit, D.; Lim, E.; Chai, H. Y.; Hollingshead, M. G.; Mayo, J. G.; Kinghorn, A. D.; Pezzuto, J. M.
  3. Cancer Letters. 2002 184(1): 13-20.
  1. 11.   Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues
  2. Liu, J.; Liu, Y. P.; Powell, D. A.; Waalkes, M. P.; Klaassen, C. D.
  3. Toxicology. 2002 170(1-2): 55-62.
  1. 12.   Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells
  2. Conze, D.; Weiss, L.; Regen, P. S.; Bhushan, A.; Weaver, D.; Johnson, P.; Rincon, M.
  3. Cancer Research. 2001 61(24): 8851-8858.
  1. 13.   Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; Is chemoprevention against multidrug resistance possible?
  2. Ratnasinghe, D.; Daschner, P. J.; Anver, M. R.; Kasprzak, B. H.; Taylor, P. R.; Yeh, G. C.; Tangrea, J. A.
  3. Anticancer Research. 2001 21(3C): 2141-2147.
  1. 14.   Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells
  2. Daschner, P. J.; Ciolino, H. P.; Plouzek, C. A.; Yeh, G. C.
  3. Breast Cancer Research and Treatment. 1999 53(3): 229-240.
  1. 15.   Tumor Necrosis Factor-Alpha and Expression of the Multidrug Resistance-Associated Genes Lrp and Mrp
  2. Stein, U.; Walther, W.; Laurencourt, C. M.; Scheffer, G. L.; Scheper, R. J.; Shoemaker, R. H.
  3. Journal of the National Cancer Institute. 1997 89(11): 807-813.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel